KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr
KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025
KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Prucalopride is prescribed for chronic idiopathic constipation
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
This is the group’s first NoC approval in Canada
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Subscribe To Our Newsletter & Stay Updated